Treatment of Hepatorenal Syndrome in Cirrhotic Patients with AKI
For cirrhotic patients with Stage 2 or greater HRS-AKI, initiate vasoconstrictor therapy (terlipressin or norepinephrine) combined with albumin immediately after diagnosis—do not wait 48 hours for a volume challenge trial. 1
Diagnostic Approach and Initial Management
After withdrawing diuretics and treating precipitating factors (especially bacterial infections), the key is rapid diagnosis within 24 hours rather than the outdated approach of a 48-hour albumin trial for all AKI cases 2. Volume expansion with IV albumin (1 g/kg body weight, maximum 100 g/day for 48 hours) should only be given to patients with clear evidence of intravascular volume depletion 3, 1.
Critical caveat: Fixed-dose albumin administration in unselected AKI patients can cause volume overload and pulmonary edema, particularly in those with cirrhotic cardiomyopathy or diastolic dysfunction 1, 2. Carefully assess volume status before albumin administration.
Vasoconstrictor Selection Algorithm
First-Line Options:
Terlipressin (preferred for non-shock HRS-AKI):
- Dosing: 0.5–2.0 mg IV every 6 hours OR continuous infusion of 2 mg/24 hours 1
- Continuous infusion achieves same efficacy with lower total daily dose and fewer side effects 1
- Reverses HRS-AKI in 36-44% of patients 1
- Contraindications: ACLF-3 (EASL-CLIF criteria), major cardiopulmonary disease, known ischemic conditions 1
- Major risk: Respiratory failure occurs in 8% of patients, especially with ACLF-3 or high pre-treatment albumin volumes 1
Norepinephrine (preferred for shock or ICU patients):
- Use as alternative to terlipressin 1
- Similar efficacy to terlipressin but requires ICU monitoring 4, 2
- First choice when AKI occurs with shock 1
Avoid This Combination:
Midodrine/octreotide should be abandoned due to lack of efficacy 2. Evidence shows no benefit over placebo in preventing AKI with SBP 3, and this combination is inferior to terlipressin or norepinephrine.
Albumin Dosing During Vasoconstrictor Therapy
Administer 20-40 g/day of albumin during vasoconstrictor treatment 1. The optimal duration remains unclear, but monitor closely for pulmonary edema, particularly in patients who received high albumin volumes pre-treatment 1.
Treatment Eligibility Criteria
Only use vasoconstrictors for Stage 2 or greater HRS-AKI 1. There is currently no recommendation for vasoconstrictor use in Stage 1 AKI. Vasoconstrictors are ineffective for other forms of AKI in cirrhosis (ATN, prerenal azotemia) because they only work when the underlying pathophysiology is splanchnic vasodilation with renal vasoconstriction 3.
Renal Replacement Therapy
RRT should be individualized but is generally recommended for patients with HRS-AKI who:
- Failed pharmacotherapy AND
- Are listed or being considered for liver transplantation 1
Definitive Treatment
Liver transplantation is the only definitive treatment for HRS-AKI 1, 5. All potential transplant candidates should be referred immediately without delay 1. Patients responding to vasoconstrictors have significantly improved post-transplant outcomes with less need for RRT and lower rates of chronic kidney disease at 1 year 1.
Key Pitfalls to Avoid
- Do not give fixed-dose albumin to all AKI patients—assess volume status first to prevent pulmonary edema 2
- Do not use terlipressin in ACLF-3 patients—respiratory failure risk is prohibitive 1
- Do not delay diagnosis beyond 24 hours—early treatment initiation is critical for efficacy 2, 6
- Do not use vasoconstrictors for non-HRS forms of AKI—they only work for HRS-AKI pathophysiology 3
- Do not continue midodrine/octreotide—switch to effective agents 2